Harold Morton Wolkin buying at Cipher Pharmaceuticals (CPH)
Harold Morton Wolkin buying at Cipher Pharmaceuticals (T:CPH)
![](https://m.canadianinsider.com/sites/default/files/home/company_profile_top_CPH1510549200.jpg)
![](https://m.canadianinsider.com/sites/default/files/home/company_volume_bottom_CPH1510549200.jpg)
Updated Monday Nov 13, 2017 03:24 AM EDT
Harold Morton Wolkin, a Director, acquired 35,000 Common Shares on a direct ownership basis at a price of $4.690 on November 10th, 2017. This represents a $164,150 investment into the company's shares and an account share holdings change of 46.2%.Cipher Pharmaceuticals is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.
Headlines: Nov 13, 2017
CPH Insider Holdings Chart
![](https://m.canadianinsider.com/sites/default/files/home/pct_chart_3.15589943422381510549200.jpg)
Issuer details as of Nov 13, 2017 3:24 ET
Latest Price
4.60
1 Day Change
-1.50%
52 Week High
5.75
52 Week Low
3.5
QMV ($Mils)
122,769,400
Issuer website: https://www.cipherpharma.com/